An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

BACKGROUND: Resistance to immune checkpoint inhibitor (ICI) therapy narrows the efficacy of cancer immunotherapy. Although 4-1BB is a promising drug target as a costimulatory molecule of immune cells, no 4-1BB agonist has been given clinical approval because of severe liver toxicity or limited effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lian-sheng, Zhu, Min, Gao, Yan, Liu, Wen-ting, Yin, Wu, Zhou, Pengfei, Zhu, Zhongliang, Niu, Liwen, Zeng, Xiaoli, Zhang, Dayan, Fang, Qing, Wang, Fengrong, Zhao, Qun, Zhang, Yan, Shen, Guodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230818/
https://www.ncbi.nlm.nih.gov/pubmed/37259060
http://dx.doi.org/10.1186/s11658-023-00461-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230818/
https://www.ncbi.nlm.nih.gov/pubmed/37259060
http://dx.doi.org/10.1186/s11658-023-00461-w

Ejemplares similares